Regenerx Biopharmaceuticals, Inc. (Amex:Rgn) (www.regenerx.com) announced today that it has been awarded an additional $136,245 from the U.S. Food and Drug Administration's (FDA's) Office of Orphan Products Development for continued development of its Tβ4 drug candidate (RGN-137) for treatment of patients with Epidermolysis Bullosa (EB), a rare and debilitating skin blistering disorder. "We are very pleased to receive this award from the FDA.
This post is an original post by ScienceDaily: Skin Care News
